Hövelmann U, et al. - In adult patients with type-1 diabetes mellitus, researchers described the pharmacokinetic and pharmacodynamic properties of dasiglucagon (a novel, stable and liquid formulated glucagon-analogue) during hypoglycemic and euglycemic conditions by analyzing data from 17 patients who received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon under euglycemic or hypoglycemic conditions. Researchers reported that dasiglucagon quickly increased plasma-glucose (PG) at doses of 0.03-0.6 mg in a dose-dependent manner, making it a suitable candidate for use in dual-hormone-artificial-pancreas-systems. In this randomized double-blind trial, nausea and vomiting occurred more frequently with dasiglucagon than with Glucagon at identical doses, possibly resulting from dasiglucagon's higher potency.